Neurobehavioral Disorders
Patients with treatment-resistant major depressive disorder or bipolar disorder without psychotic symptoms received intravenous infusions of 0.5 mg/kg ketamine 3 times per week for 2 weeks.
Neurobehavioral Disorders
Researchers examined the effect of neuropeptides orexin-A, ghrelin, and neuropeptide Y on hypersomnia and hyperphagia. Both symptoms are more common in people with bipolar disorder.
Neurobehavioral Disorders
The researchers of this study explored the impact of a blended approach (bCBT) that included both face-to-face CBT and iCBT on patients with major depressive disorder and insomnia.
Neurobehavioral Disorders
Reddit posts from forums discussing self-harm were used to characterize and quantify the addiction language and to evaluate the extent to which individuals who engage in self-harm feel they are suffering from an addiction.
Neurobehavioral Disorders
Two experts speak about how apps address different needs and use different technologies, but taken together, they shed light on the manifold ways that apps can be used for depression management in clinical practice.
Neurobehavioral Disorders
Whether major depressive disorder is a comorbidity of bipolar disorder isn’t really known. Researchers built a predictive model of major depressive disorder to bipolar disorder conversion and with the Observational Medical Outcomes Partnership validated the results across a multi-national network of patient databases.
Neurobehavioral Disorders
Registries databases were searched for randomized controlled trials published between 1952 and 2020 that evaluated psychological interventions for adults diagnosed with bipolar I or bipolar II disorder.
Neurobehavioral Disorders
Investigators report the findings from a study assessing the impact of insomnia on clinical outcomes in patients with major depressive disorder.
Neurobehavioral Disorders
AXS-05 consists of dextromethorphan, an NMDA receptor antagonist, and bupropion, a norepinephrine and dopamine reuptake inhibitor.
Neurobehavioral Disorders
Investigators conducted a systematic review of studies published between January 1, 2020 and January 29, 2021 that estimated the prevalence of major depressive disorder and anxiety disorders during the COVID-19 pandemic.
